Comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer”

Comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer”

Saved in:

Bibliographic Details
Main Authors:	Chenglong Wang, Shuai An, Fang-Tong Liu
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-04-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/4/e012221.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer
by: Yoon-Koo Kang, et al.
Published: (2025-03-01)

Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer”
by: Yoon-Koo Kang, et al.
Published: (2025-05-01)

Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States
by: Caicong You, et al.
Published: (2025-07-01)

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
by: Narek Shaverdian, et al.
Published: (2020-07-01)

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer Treatment: Insights from the TOPAZ-1 Trial
by: Ralph Fritsch
Published: (2024-10-01)

TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer
by: Heather L. McArthur, et al.
Published: (2025-02-01)

Feasibility and predictive factors on the completion of docetaxel plus S‐1 adjuvant chemotherapy in pathological stage III gastric cancer
by: Masayoshi Terayama, et al.
Published: (2025-01-01)

Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study
by: T. De La Motte Rouge, et al.
Published: (2025-10-01)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
by: Jean-Charles Soria, et al.
Published: (2020-10-01)

First-line durvalumab plus platinum–etoposide in Japanese patients with extensive-stage small-cell lung cancer
by: Eisuke Mochizuki, et al.
Published: (2025-01-01)

Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice
by: Tetsu Tomonari, et al.
Published: (2024-10-01)

Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers
by: Mayur Patel, et al.
Published: (2025-05-01)

Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003)
by: Hidenobu Ishii, MD, PhD, et al.
Published: (2025-07-01)

Updated efficacy and safety data from a phase II, single-arm, open-label study of durvalumab plus gemcitabine, cisplatin, and nab-paclitaxel (DurGAP) in resectable biliary tract cancer
by: Huikai Li, et al.
Published: (2025-02-01)

Novel use of carboplatin, etoposide and durvalumab as neoadjuvant therapy in treatment of small cell bladder cancer
by: Victoria Gonzalez, et al.
Published: (2025-09-01)

Phase 1 trial of durvalumab (anti–PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma
by: Christiane Querfeld, et al.
Published: (2025-05-01)

A pharmacovigilance analysis of post-marketing safety of durvalumab
by: An-Ju Tan, et al.
Published: (2025-05-01)

Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab
by: Naohiro Watanabe, et al.
Published: (2025-04-01)

Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the US payer perspective
by: Bin Li, et al.
Published: (2025-04-01)

First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis
by: Ling Fang, et al.
Published: (2023-12-01)

Comparison of PSOX (paclitaxel, oxaliplatin, S-1) and SOX (oxaliplatin, S-1) as postoperative adjuvant chemotherapy for stage II-III gastric cancer
by: Fei-Yu Wang, et al.
Published: (2025-03-01)

Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab
by: Alfredo S. Golemba, MD, et al.
Published: (2025-05-01)

High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab
by: Ciani Ellison, MD, et al.
Published: (2024-12-01)

Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8
by: Udo S Gaipl, et al.
Published: (2020-10-01)

TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
by: Peter Schmid, et al.
Published: (2025-04-01)

Durvalumab-Associated Crescentic Glomerulonephritis With IgA Vasculitis-Like Features
by: Tao Zhao, et al.
Published: (2025-07-01)

Higher Absolute Lymphocyte Counts and Lower Des‐γ‐Carboxyprothrombin Levels After Treatment Initiation Are Associated With the Clinical Efficacy of Tremelimumab Plus Durvalumab Combination Therapy for Hepatocellular Carcinoma
by: Yuta Inoue, et al.
Published: (2025-02-01)

The clinical outcomes of adjuvant gemcitabine plus S-1 in resected pancreatic cancer: a single-center retrospective study
by: Kuan-Yu Tseng, et al.
Published: (2025-07-01)

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
by: Drew M Pardoll, et al.
Published: (2020-10-01)

Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial
by: Nan Niu, et al.
Published: (2025-07-01)

Clinical outcomes of transarterial chemoembolization combined with durvalumab for advanced and metastatic biliary tract cancer
by: Yuefeng Hu, et al.
Published: (2025-12-01)

Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer
by: Karen A. Autio, et al.
Published: (2025-04-01)

Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC
by: Masayuki Shirasawa, et al.
Published: (2025-01-01)

Effectiveness of neoadjuvant chemotherapy with a docetaxel, cisplatin, and S-1 (DCS) regimen for T4b gastric cancer
by: Vo Duy Long, et al.
Published: (2024-12-01)

Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study
by: Pernelle Lavaud, et al.
Published: (2025-01-01)

Neoadjuvant chemotherapy plus anlotinib in the treatment of resectable head and neck squamous cell carcinoma: A pilot phase II trial
by: Qianting He, et al.
Published: (2025-05-01)

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
by: Yan Wang, et al.
Published: (2022-03-01)

Autoantibody spark response predicts treatment outcome in patients receiving chemoradiation followed by durvalumab therapy
by: Takeru Mori, et al.
Published: (2025-07-01)

Durvalumab Combined With Pemetrexed-Based Chemotherapy in Trial-Ineligible Patients With Mesothelioma: A Brief Report
by: Ibiayi Dagogo-Jack, MD, et al.
Published: (2025-05-01)

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
by: Chao Zhang, et al.
Published: (2020-10-01)